In our present study, we showed that mTORC2 signaling is a positive regulator of HR-mediated repair and that targeting mTORC2 kinase significantly decreases HR-mediated repair capacity in pancreatic cancer cells, which consequently increases sensitivity to PARP inhibitors. Here, PARP1 is linked to pancreatic neoplasm.